Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
BioNTech (NASDAQ:BNTX) Stock Gets Price Target Boost from JPMorgan Chase & Co.
BioNTech (BNTX) Has Fresh Attention, So What Is The Market Weighing?
Money talks: BioNTech spends $205 million to jump the FDA queue
Pictet Asset Management Holding SA Acquires 20,777 Shares of BioNTech SE Sponsored ADR $BNTX - Markets Daily
BioNTech (NASDAQ:BNTX) Stock Gets Price Target Cut from HC Wainwright - Markets Daily
BioNTech SE Sponsored ADR $BNTX Stock Purchased by Pictet Asset Management Holding SA - Stock Observer
BioNTech (BNTX) Stock Looks Above Fair Value On Current Sales
BNTX Maintained by HC Wainwright & Co. -- Price Target Lowered t
HC Wainwright Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech SE Sponsored ADR $BNTX Shares Newly Bought by Mirae Asset Global Investments Co. Ltd. - Markets Daily
BioNTech SE Sponsored ADR $BNTX Shares Newly Bought by Mirae Asset Global Investments Co. Ltd. - Zolmax
BioNTech (NASDAQ:BNTX) Stock Price Target Lowered at HC Wainwright - Stock Observer
Wall Street Zen Upgrades BioNTech (NASDAQ:BNTX) to Hold - Zolmax
BioNTech (NASDAQ:BNTX) Stock Bumped Up to "Hold" by Wall Street Zen - Markets Daily
BioNTech SE Sponsored ADR $BNTX Stock Position Increased by Candriam S.C.A. - Daily Political
BioNTech (NASDAQ:BNTX) Stock Gets Price Target Trim from Wells Fargo & Company
BioNTech (BNTX) Returned To Profit And Lifted Guidance, Is It A Bargain?
156,750 BioNTech SE Sponsored ADR $BNTX Shares Sold by CenterBook Partners LP
BioNTech (NASDAQ:BNTX) Stock Gets Price Target Reduction from Morgan Stanley - Stock Observer
BioNTech (NASDAQ:BNTX) Stock Moved Up to Hold by Wall Street Zen
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
BioNTech (NASDAQ:BNTX) Stock Price Target Lowered at UBS Group - Stock Observer
Morgan Stanley Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX) Stock Price Target Lowered at Wells Fargo & Company
BioNTech Earnings: Guidance Narrowed Higher Despite Lower Covid Vaccine Sales | Morningstar
BioNTech (BNTX) Enters First Global Phase 3 Trial For New Breast Cancer Combo
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial
BioNTech Q3 Earnings Call Highlights
BioNTech (BNTX) Q3 2026 Earnings Date, Time & Estimates
BioNTech Reports Q3 Net Profit; Revenue Falls 15% On Lower COVID-19 Vaccine Demand
BioNTech Q3 Results Show Return To Profitability; Oncology Programs Advance
BioNTech Lifts Outlook on Cancer Drug Milestone Payments (1)
Clinics: Lynk JAK1 inhibitor meets primary endpoint in RA | BioWorld
Critical Review: BioNTech (NASDAQ:BNTX) & I-Mab (NASDAQ:NBP) - Zolmax
Stocktwits Pharma Pulse: Biotech Beats The Broader Market - Novo, Pfizer And Moderna Earnings Up Next
Head to Head Contrast: I-Mab (NASDAQ:NBP) & BioNTech (NASDAQ:BNTX) - Daily Political
BioNTech founders receive science award - Türkiye News
Travere Therapeutics (NASDAQ:TVTX) versus BioNTech (NASDAQ:BNTX) Head to Head Contrast - Daily Political
Head to Head Analysis: Xencor (NASDAQ:XNCR) & BioNTech (NASDAQ:BNTX) - Stock Observer
BioNTech (BNTX) Posts Fresh Cancer Trial Progress, Is It Still 24% Below Fair Value?
Head and Neck Squamous Cell Carcinoma Market Size in the 7MM is projected to reach nearly USD 2,560 million by 2036, growing at a CAGR of 10.5% during 2026-2036 | DelveInsight | ABNewswire
BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety Warning
Financial Comparison: BioNTech (NASDAQ:BNTX) & Travere Therapeutics (NASDAQ:TVTX) - Markets Daily
The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
BioNTech (BNTX) Projected to Release Quarterly Earnings on Tuesday
BioNTech SE Sponsored ADR $BNTX Stock Sold by Robeco Institutional Asset Management B.V.
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate
BioNTech, Bristol Myers' Pumitamig Shows 36.7% Response Rate In Phase 2 NSCLC Trial
BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?
Berenberg Bank Sticks to Their Hold Rating for Qiagen (QGEN)
Sterling Capital Management LLC Acquires 88,344 Shares of Gilead Sciences, Inc. $GILD - Stock Observer
7,751 Shares in Gilead Sciences, Inc. $GILD Bought by NBT Bank N.A. - Daily Political
Gilead Sciences, Inc. $GILD Stock Holdings Raised by Royal Fund Management LLC - Zolmax
Gilead Sciences, Inc. $GILD Stock Bought by Royal Fund Management LLC - Markets Daily
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
BioNTech Expands Phase 3 Breast Cancer Trial Through Collaboration With Gilead
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Morningstar
BioNTech news
Latest news
Show more
Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty
September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations
Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge
